Atezolizumab for the First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): Current Status and Future Prospects

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2018.00277
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development

Oncologist
Cancer ResearchMedicineOncology
2007English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

Analysis of Continuous First‑line Treatment With Docetaxel and Carboplatin for Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2014English

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Small Cell Lung Cancer: Current and Future Strategies

Oncomedicine
2016English

Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions

Oncologist
Cancer ResearchMedicineOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy